Forest Laboratories, Inc., a New York-based pharmaceutical company, announced that it will present data on TUDORZA PRESSAIR (aclidinium bromide inhalation powder), a combination use of aclidinium bromide/formoterol fumarate, and DALIRESP (roflumilast). The presentations were held at the American Thoracic Society (ATS) 2014 International Conference on May 16-21, 2014, in San Diego.
For aclidinium and aclidinium/formoterol, 10 posters and 2 poster discussion sessions were presented. For roflumilast, 4 posters highlighting the data and 1 mini-symposia presentation were presented. To review the program for the ATS 2014 International Conference, click here.
According to the estimation of the World Health Organization (WHO), 64 million people worldwide are affected by COPD. The disease is the third leading cause of death in the U.S. The airways in lungs of COPD patients typically lose their elasticity, produce excess mucus and become thick and inflamed. Patients could experience breathlessness, abnormal sputum and chronic cough.
TUDORZA PRESSAIR is an anticholinergic used as a long term therapy to treat bronchospasm, chronic bronchitis, and emphysema associated with chronic obstructive pulmonary disease (COPD). It is taken by inhalation and produces bronchodilation by inhibiting the muscarinic M3 receptor in the airway smooth muscle.
Aclidinium bromide/formoterol fumarate is an investigational fixed dose combination of two approved long-acting bronchodilators.
DALIRESP is a selective PDE4 inhibitor used to reduce the risk of exacerbations in patients with severe COPD. DALIRESP is not a bronchodilator and is not indicated for the relief of acute bronchospasm.